September 29, 2025 – Kedrion Biopharma announced a major regulatory and strategic milestone with the U.S. Food and Drug Administration (FDA) approval of QIVIGY®, a new 10% intravenous immunoglobulin (IVIG) therapy for adults with Primary Humoral Immunodeficiency (PI). The approval not only introduces an important new treatment for patients with rare immune disorders but also reinforces Kedrion’s commitment to accelerating investments across its U.S. operations and global network.
Science Significance
QIVIGY® is a 10% IVIG therapy developed entirely within Kedrion’s own research and manufacturing ecosystem in the United States and Italy. It is designed to treat adults with Primary Humoral Immunodeficiency—a group of disorders that leave patients vulnerable to serious, recurrent infections. Clinical trial data demonstrated that QIVIGY® patients experienced fewer infections and reduced time away from work and school, underscoring its potential to significantly improve quality of life for those living with these chronic conditions. The therapy expands the range of available immunoglobulin treatments and highlights Kedrion’s scientific expertise in plasma-derived biologics.
Regulatory Significance
FDA approval of QIVIGY® represents Kedrion’s first U.S. product clearance since its April 2025 rebranding, signaling the company’s enhanced regulatory capabilities and growth trajectory. The product is expected to launch first in the U.S. in early 2026, with additional global rollouts planned for Europe and other markets pending regulatory authorization. This achievement strengthens Kedrion’s position in the highly competitive plasma-therapy market and reinforces its ability to successfully navigate complex global regulatory pathways.
Business Significance
Advertisement
The FDA approval of QIVIGY® paves the way for significant commercial growth. Kedrion plans to invest over $260 million to develop more than 40 new U.S. plasma collection centers over the next several years, ensuring robust supply for its plasma-derived products. In addition, the company is allocating over $60 million to expand manufacturing capacity at its Melville, New York facility, $80 million for IT infrastructure and clinical studies, and $15 million for the U.S. product launch. These investments underscore Kedrion’s long-term strategy to strengthen its global footprint and meet rising demand for rare disease therapies.
Patients’ Significance
Primary Immunodeficiency Disorders (PID) encompass more than 550 rare, chronic conditions where components of the immune system are either missing or impaired. An estimated 500,000 Americans currently live with PID, though experts suspect the true figure may be significantly higher due to underdiagnosis or misdiagnosis. By introducing QIVIGY®, Kedrion is addressing a critical unmet need, offering a therapy that helps prevent infections and supports patients’ daily activities. “This FDA approval reflects not only our scientific and operational capabilities but also the heart and purpose that drive our mission to serve patients,” said Ugo Di Francesco, Kedrion’s Chief Executive Officer.
Policy Significance
Kedrion’s U.S. investments support national health policy goals around domestic manufacturing and rare disease innovation. By expanding plasma collection and manufacturing capacity within the United States, Kedrion strengthens supply chain security for essential biologics while advancing the development of life-saving therapies. The company’s long-term commitment to R&D also aligns with policy initiatives aimed at improving treatment access and fostering innovation for rare and underserved patient populations.
Transaction Highlights
Kedrion Biopharma’s latest FDA approval of QIVIGY® is accompanied by a multi-phase global expansion strategy that underscores its commitment to both patients and market growth. The company will launch QIVIGY® first in the United States in early 2026, with regulatory submissions planned for Europe and other international markets to follow. To support this rollout and future product development, Kedrion is making significant capital investments across its U.S. operations, including over $260 million to expand its plasma collection network through the development of more than 40 new collection centers, $60 million to increase manufacturing capacity at its Melville, New York facility, and $80 million to enhance IT infrastructure and fund clinical studies. Additionally, Kedrion has allocated more than $15 million specifically for the U.S. product launch of QIVIGY®, ensuring robust commercialization and distribution. These coordinated investments strengthen the company’s manufacturing resilience, secure a reliable plasma supply chain, and enable Kedrion to meet growing global demand for plasma-derived therapies while advancing its long-term growth strategy.
Source: Kedrion Biopharma Press Release
